WO1996037610A3 - Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders - Google Patents

Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders Download PDF

Info

Publication number
WO1996037610A3
WO1996037610A3 PCT/IB1996/000696 IB9600696W WO9637610A3 WO 1996037610 A3 WO1996037610 A3 WO 1996037610A3 IB 9600696 W IB9600696 W IB 9600696W WO 9637610 A3 WO9637610 A3 WO 9637610A3
Authority
WO
WIPO (PCT)
Prior art keywords
cck
signal transduction
methods
diagnosis
treatment
Prior art date
Application number
PCT/IB1996/000696
Other languages
French (fr)
Other versions
WO1996037610A2 (en
Inventor
Axel Ullrich
Kevin Mossie
Frauke Alves
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Priority to AU62386/96A priority Critical patent/AU6238696A/en
Publication of WO1996037610A2 publication Critical patent/WO1996037610A2/en
Publication of WO1996037610A3 publication Critical patent/WO1996037610A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Abstract

The present invention relates to CCK-4 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for diseases or conditions characterized by an abnormality in a signal transduction disorder. The signal transduction pathway involves an interaction between a CCK-4 receptor tyrosine kinase and a receptor for the kinase.
PCT/IB1996/000696 1995-05-25 1996-05-24 Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders WO1996037610A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62386/96A AU6238696A (en) 1995-05-25 1996-05-24 Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45263095A 1995-05-25 1995-05-25
US08/452,630 1995-05-25

Publications (2)

Publication Number Publication Date
WO1996037610A2 WO1996037610A2 (en) 1996-11-28
WO1996037610A3 true WO1996037610A3 (en) 1997-01-16

Family

ID=23797255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/000696 WO1996037610A2 (en) 1995-05-25 1996-05-24 Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders

Country Status (2)

Country Link
AU (1) AU6238696A (en)
WO (1) WO1996037610A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
WO2005063987A1 (en) * 2003-12-19 2005-07-14 Aveo Pharmaceuticals, Inc. Gp153: methods and compositions for treating cancer
DK1957539T3 (en) 2005-12-08 2013-05-06 Medarex Inc HUMAN MONOCLONAL ANTIBODIES FOR PROTEINTYROSINKINASE 7 (PTK7) AND THEIR USE
EP2380909A1 (en) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHOU, Y.-H. AND HAYMAN, M.J.: "Characterization of a member of the immunoglobulin gene superfamily that possibly represents an additional class of growth factor receptor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 88, June 1991 (1991-06-01), pages 4897 - 4901, XP000605384 *
LEE, S.-T. ET AL.: "A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes", ONCOGENE, vol. 8, 1993, pages 3403 - 3410, XP002016719 *
MOSSIE, K. ET AL.: "Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family", ONCOGENE, vol. 11, no. 10, 1995, pages 2179 - 2184, XP000605662 *
PARK, S.-K. ET AL.: "Characterization of the human full-length PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule closely related to chick KLG", THE JOURNAL OF BIOCHEMISTRY, vol. 119, February 1996 (1996-02-01), pages 235 - 239, XP000605383 *
TAN, J.C. ET AL.: "The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase", SCIENCE, vol. 247, 12 January 1990 (1990-01-12), pages 209 - 212, XP000608226 *
ULLRICH, A. AND SCHLESINGER, J.: "Signal transduction by receptors with tyrosine kinase activity", CELL, vol. 61, April 1990 (1990-04-01), pages 203 - 212, XP000471628 *

Also Published As

Publication number Publication date
WO1996037610A2 (en) 1996-11-28
AU6238696A (en) 1996-12-11

Similar Documents

Publication Publication Date Title
CA2239692A1 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
WO1999037788A3 (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
WO1998031799A3 (en) Polynucleotides and polypeptides encoding receptors
WO1999058675A3 (en) Human genes and gene expression products v
EP0771873A3 (en) Neuronal cell-specific receptor protein
WO2000000610A3 (en) Human signal peptide-containing proteins
WO1999024463A3 (en) Signal peptide-containing proteins
DK0842273T3 (en) Receptor ligand VGEF-C
CA2250075A1 (en) Methods for diagnosing and treating alzheimer's disease
CA2145182A1 (en) Dna encoding human alpha 1 adrenergic receptors and uses thereof
WO1997021811A3 (en) Novel tyrosine kinase receptors and ligands
Lorigados et al. Two‐site enzyme immunoassay for βNGF applied to human patient sera
WO1999007738A3 (en) Human orphan receptor ntr-1
WO1998026054A3 (en) Pyk2 related products and methods
WO2002086076A3 (en) Polynucleotides and polypeptides associated with the nf-kb pathway
EP0789076A3 (en) G protein coupled receptor proteins, their production and use
WO1996037610A3 (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
WO1997020045A3 (en) P2u2 purinergic receptor
MX9606584A (en) Mass-sensitive biosensors.
WO2002057460A3 (en) Polynucleotides encoding human phosphatases
WO1998049317A3 (en) Diagnosis and treatment of phosphatase- 0r kinase-related disorders
WO2001040291A3 (en) Proteins and nucleic acids encoding the same
DE69626860T2 (en) ELISA TEST SYSTEM FOR DETERMINING SUBSTANCES INHIBITING THE BOND BETWEEN IG E AND ITS RECEPTOR
EP1443055A3 (en) Interleukins-21 and 22

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA